Akero Therapeutics, INC Form 4 insider transactions
Akero Therapeutics' Chief Development Officer, Catriona Yale, sold 2,803 shares of common stock for approximately $53.996 per share to cover tax withholding obligations related to the vesting of restricted stock units.
Akero Therapeutics' Senior VP, Commercial Strategy, Patrick Lamy, sold 919 shares of common stock at a weighted-average price of $53.999 to cover tax withholding obligations related to restricted stock unit vesting.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 2,493 shares of common stock for approximately $53.99 per share to satisfy tax withholding obligations related to restricted stock unit vesting.
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, executed a series of pre-planned option exercises and subsequent share sales totaling approximately $2.05 million in early June 2025.
Akero Therapeutics, Inc. Director Jane Henderson has acquired 9,398 shares of common stock in the form of restricted stock units, vesting on the earlier of June 3, 2026, or the next annual meeting.
Akero Therapeutics, Inc. Director Seth Loring Harrison was granted 9,398 restricted stock units (RSUs) on June 3, 2025, as part of his compensation.
Akero Therapeutics, Inc. Director Mark T. Iwicki was granted 9,398 restricted stock units (RSUs) on June 3, 2025, which will vest based on continued service.
Akero Therapeutics, Inc. Director Yuan Xu was granted 9,398 shares of common stock in the form of Restricted Stock Units (RSUs) as part of a standard compensation arrangement.
Akero Therapeutics, Inc. Director Tomas J. Heyman was granted 9,398 restricted stock units (RSUs) as part of his compensation, aligning his interests with the company's long-term performance.
Akero Therapeutics, Inc. director Judy Chou was granted 9,398 shares of common stock in the form of Restricted Stock Units (RSUs) as part of her compensation.
Form 4: Akero Therapeutics Director Increases Direct Stock Ownership Through Restricted Stock Unit Grant
Akero Therapeutics, Inc. Director Graham G. Walmsley reported the acquisition of 9,398 restricted stock units, increasing his direct beneficial ownership in the company.
Form 4: Akero Therapeutics Senior VP Exercises Stock Options and Sells Shares Under Pre-Arranged 10b5-1 Plan
Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, executed a pre-planned transaction on June 2, 2025, involving the exercise of stock options and the subsequent sale of an equivalent number of shares.
Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, exercised stock options and simultaneously sold 4,000 shares of common stock on May 22, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Akero Therapeutics Chief Development Officer Catriona Yale Executes Stock Option and Sells Shares
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock on May 15, 2025, according to a Form 4 filing with the SEC.
Akero Therapeutics' CEO, Andrew Cheng, sold shares of common stock on May 12, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, sold shares of common stock and exercised stock options under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, Executes Stock Option and Sells Shares
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Akero Therapeutics' CEO, Andrew Cheng, sold 30,000 shares of common stock on April 10, 2025, at a weighted average price of $35.226 per share.
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Director Graham G. Walmsley reports acquisition of Akero Therapeutics shares through indirect holdings.
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares on March 17, 2025, according to a recent SEC filing.
Akero Therapeutics CEO Andrew Cheng sold 1,738 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 607 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Catriona Yale, Chief Development Officer of Akero Therapeutics, sold 614 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.
William Richard White, CFO of Akero Therapeutics, sold 676 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, sold 516 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Akero Therapeutics' CEO, Andrew Cheng, executed sales of common stock on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.